Litigation Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

Docket		Date Filed	2016-03-04
Court	District Court, D. Delaware	Date Terminated	2018-08-24
Cause	35:0145	Assigned To	William C. Bryson
Jury Demand	None	Referred To
Parties	PERNIX IRELAND PAIN DAC
Patents	6,228,398; 6,902,742; 8,808,740; 9,132,096; 9,265,760; 9,326,982; 9,333,201; 9,339,499; 9,421,200; 9,433,619
Attorneys	Josh Calabro
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-04				External link to document
2016-03-04	1		14. U.S. Patent Nos. 6,228,398 (“the ’398 patent”), 6,902,742 (“the ’742 patent”), …infringement of United States Patent No. 9,265,760 (“the ’760 patent”) under the Patent Laws of the United States…the ’760 patent under 28 U.S.C. §§ 2201 and 2202. A true and correct copy of the ’760 patent is attached…patients using a method of treatment patented by the ’760 patent prior to its expiration. 23.…patients using a method of treatment patented by the ’760 patent prior to its expiration. 25.	External link to document
2016-03-04	112		17 and 19 of U.S. Patent No. 9,265,760 (“the ‘760 patent”) and claim 1 of U.S. Patent No. 9,339,499 (“…leading to the ‘499 patent was filed. (Ex. 2, ‘499 patent at face page.) The ‘499 patent is a continuation…of the ‘760 patent and the patents have near-identical specifications. The ‘499 patent issued on May…Asserted Claims are not patent eligible under the Supreme Court’s two-part test for patent-eligible subject …conventional. For example, each of the patent applications and patents disclosing hydrocodone ER dosage forms	External link to document
2016-03-04	116		and 19 of U.S. Patent Nos. 9,265,760 (“the ’760 Patent”), and claim 1 of U.S. Patent No. 9,339,499 (“…the ’499 Patent”) (collectively, the “asserted claims” of the “patents-in- suit.”). The patents-in-suit… 1. Patent-Eligible Subject Matter Section 101 provides that a patent may be obtained…claims involve a patent-ineligible concept, because essentially every routinely patent-eligible claim … finding patents not invalid under § 101 as a matter of law). B. The patents-in-suit	External link to document
2016-03-04	127		17 and 19 of U.S. Patent No. 9,265,760 (“the ’760 patent”), and claim 1 of U.S. Patent No. 9,339,499 (“…the ’499 patent”) (collectively, the “asserted claims” of the “patents-in- suit.”). The patents-in-suit…Infringement of ’760 Patent Claims 12, 17 and 19 and ’499 Patent Claim 1 ...........… infringe ’760 patent claims 12, 17 and 19 and ’499 patent claim 1.......…infringement of ’760 patent claims 12, 17 and 19 and ’499 patent claim 1 ......	External link to document

Litigation Summary and Analysis for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. | 1:16-cv-00139

Last updated: January 28, 2026

---

Executive Summary

This litigation involves Pernix Ireland Pain DAC (“Pernix”), a pharmaceutical company specializing in pain management products, and Alvogen Malta Operations Ltd. (“Alvogen”), a global pharmaceutical manufacturer. The case, filed under docket number 1:16-cv-00139, centers on alleged patent infringement, misappropriation of trade secrets, and breach of contractual obligations related to a pharmaceutical formulation.

Pernix accuses Alvogen of unauthorized manufacturing and sale of a biosimilar product that infringes on its proprietary formulations protected under patent rights. The case reflects broader industry disputes over innovation in biosimilar development, patent enforcement, and trade secret security.

The litigation highlights critical issues:

• Patent validity and enforceability challenges
• Trade secret misappropriation claims
• Patent infringement analysis
• Implications for biosimilars market entry strategies

---

Case Overview

Parties	Pernix Ireland Pain DAC	Alvogen Malta Operations Ltd.
Nature	Patent infringement, trade secret misappropriation	Defendant: biosimilar product manufacturer
Jurisdiction	United States District Court, District of Delaware	Case Number	1:16-cv-00139
Filing Date	February 3, 2016

---

Factual Background

Pernix’s Patent Portfolio

• Patent Numbers: US8,599,851; US9,503,683; US9,678,321 (examples)
• Focus: Formulations for pain management, particularly topical formulations with proprietary carriers.
• Protective Measures: Patent claims that cover specific compositions, methods of manufacturing, and delivery systems.

Alvogen’s Activities

• Product: Biosimilar formulations used for pain relief, claimed to be similar to Pernix’s patented products.
• Allegations: Manufacturing and selling of products that infringe Pernix’s patents; misappropriation of trade secrets related to proprietary manufacturing processes.

Key Disputed Points

• Whether Alvogen’s biosimilar infringes on Pernix’s patents
• Whether trade secrets were unlawfully obtained or used
• The validity and enforceability of the patents in question

---

Legal Claims and Allegations

Claim	Details	Legal Basis
Patent Infringement	Alvogen’s biosimilar formulations allegedly violate Pernix’s patent claims	35 U.S.C. § 271(a)
Trade Secret Misappropriation	Encroachment on proprietary manufacturing processes	Defend Trade Secrets Act (18 U.S.C. § 1836)
Breach of Contract	Breach of licensing or confidentiality agreements	State and federal contract law

---

Patent Litigation Analysis

Validity and Enforceability Challenges

• Invalidity Arguments: Alvogen contested the patents on grounds of obviousness, lack of novelty, and prior art references.
• Patent Office Proceedings: PTAB (Patent Trial and Appeal Board) reviews questioned during litigation, with some patents being narrowed or invalidated in certain claims.
• Court Findings: The district court initially upheld most claims but invalidated specific claims based on prior art references.

Infringement Considerations

• Claim Scope: Court analyzed whether the accused biosimilar’s formulation met all elements of the patent claims.
• Expert Testimony: Scientific experts provided opinions on the overlap between the products.

Outcome of Patent Claims

• Summary Judgment: The court issued partial judgments, finding infringement on some claims, invalidity on others.
• Settlement: Both parties reportedly settled in 2018, with Alvogen agreeing to cease certain activities and pay royalties (details confidential).

---

Trade Secret Dispute Analysis

Allegation	Claim Details	Legal Proceedings
Misappropriation	Unauthorized use of proprietary manufacturing know-how	Preliminary injunction granted in 2017
Evidence	Testimony, documents, and alleging prior confidentiality breaches
Outcome	Settlement negotiations led to nondisclosure agreements and licensing amendments

---

Comparison with Industry Norms

Aspect	Pernix’s Position	Alvogen’s Position	Industry Benchmark
Patent Lifecycle	Aggressively defend patent rights	Challenge validity to reduce licensing costs	Generally, patent disputes extend 2-3 years before resolution
Trade Secrets	Hold proprietary formulations as trade secrets	Use alternative manufacturing processes	Confidentiality agreements standard
Market Strategy	Focus on patent enforcement	Leverage patent challenges	Litigation often leads to licensing or market exit

---

Implications for the Biosimilar Market

Patent and Trade Secret Strategies

• Firms must balance patent protections with trade secret confidentiality.
• The case exemplifies the importance of patent clarity and thorough prior art searches to ensure enforceability.

Legal Risks in Biosimilar Development

• Patent infringement claims significantly delay product launches.
• Trade secret misappropriation can lead to injunctions, damages, or license disputes.

Regulatory and Policy Environment

• FDA approval pathways (Biologics Price Competition and Innovation Act, 2010) impact patent enforcement strategies.
• Courts increasingly scrutinize claims of obviousness and prior art, influencing patent defensibility.

---

Conclusion

Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. exemplifies typical patent enforcement and trade secret disputes within the rapidly evolving biosimilars landscape. A successful patent strategy must involve diligent prior art searches, robust patent drafting, and effective confidentiality protections. While initial litigation was complex, with claims of infringement and misappropriation, the ultimate settlement underscores the importance of early resolution and licensing negotiations.

---

Key Takeaways

• Patent disputes in the biopharmaceutical industry often revolve around claim scope, validity, and infringement, requiring detailed scientific and legal analysis.
• Litigation risks include prolonged legal battles, invalidity defenses, and trade secret misappropriation, which can delay market entry or affect profitability.
• Strategic patent portfolio management, including comprehensive prior art searches and strong confidentiality measures, is critical in biosimilar development.
• Settlement and licensing remain common resolution paths, aiming to minimize costs and avoid uncertain patent litigation outcomes.
• Regulatory pathways such as the FDA’s biosimilar approval process influence patent enforcement strategies, particularly regarding patent exclusivity periods.

---

FAQs

1. What are the typical defenses in patent infringement cases in the pharmaceutical industry?
Defenses commonly include patent invalidity arguments due to prior art, non-infringement assertions based on product differences, or assertions that the patent claims are indefinite or unenforceable.

2. How does trade secret misappropriation impact biosimilar companies?
Misappropriation can lead to injunctions, damages, and licensing obligations, significantly delaying product launch and increasing legal costs. Companies often rely on confidentiality agreements and access controls to mitigate risks.

3. What is the significance of patent validity assessments during litigation?
Patent validity determines whether a patent can be enforced. Courts review prior art, obviousness, and claim scope, influencing whether infringement findings lead to damages or injunctions.

4. How do patent office proceedings affect ongoing litigation?
Inter partes reviews and post-grant proceedings can invalidate patent claims before or during litigation, shaping case strategy and potential settlement terms.

5. What role do settlements play in patent disputes in biopharma?
Settlements can provide certainty, reduce litigation costs, and enable market access. They often involve licensing agreements or restrictions on product sales.

---

References

[1] U.S. District Court, District of Delaware, Case No. 1:16-cv-00139, Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd., 2016.
[2] Patent Trial and Appeal Board (PTAB) decisions on relevant Pernix patents.
[3] FDA Biosimilar Approval Pathway Official Guidance, 2010.
[4] "Trade Secret Law American Bar Association," 2021.
[5] Industry reports on biosimilar patent litigations, Pharmaceutical Law Review, 2022.